Using a bioinformatics-based strategy, we set out to identify hypermethylated genes that could serve as biomarkers for early detection of colorectal cancer (CRC) in stool. In addition, the complementary value to a Fecal Immunochemical Test (FIT) was evaluated. Candidate genes were selected by applying cluster alignment and computational analysis of promoter regions to microarray-expression data of colorectal adenomas and carcinomas. DNA methylation was measured by quantitative methylation-specific PCR on 34 normal colon mucosa, 71 advanced adenoma, and 64 CRC tissues. The performance as biomarker was tested in whole stool samples from in total 193 subjects, including 19 with advanced adenoma and 66 with CRC. For a large proportion of these series, methylation data for GATA4 and OSMR were available for comparison. The complementary value to FIT was measured in stool sub-samples from 92 subjects including 44 with advanced adenoma or CRC. Phosphatase and Actin Regulator 3 (PHACTR3) was identified as a novel hypermethylated gene showing >70-fold increased DNA methylation levels in advanced neoplasia compared to normal colon mucosa. In a stool training set, PHACTR3 methylation showed a sensitivity of 55% (95% confidence interval(CI95%) 33-75%) for CRC and a specificity of 95% (CI95%87-98%). In a stool validation set, sensitivity reached 66% (CI95%50-79%) for CRC and 32% (CI95%14-57%) for advanced adenomas at a specificity of 100% (CI95%86-100%). Adding PHACTR3 methylation to FIT increased sensitivity for CRC up to 15%. PHACTR3 is a new hypermethylated gene in CRC with a good performance in stool DNA testing and has complementary value to FIT.
Introduction
Screening for colorectal cancer (CRC) is the most efficient strategy for reducing death from this devastating disease. Colonoscopy is the gold standard for the detection and removal of early lesions and is highly sensitive, but also invasive and costly 1, 2 . For population-wide screening a simple and non-invasive procedures like stool testing are preferred 3 . In follow up to the guaiac-based Faecal Occult Blood Test (FOBT), the more sensitive immunochemical fecal occult blood test (Fecal Immunochemical Test or FIT) [4] [5] [6] is now widely used in screening programs in Europe and Japan, and is expected to reduce CRC mortality by around 30% 7 . This test performance though, still leaves room for improvement which could come from molecular stool tests like those testing for tumor DNA in stool. Multiple assays have been developed and evaluated for this purpose, but sensitivities still remain suboptimal [8] [9] [10] [11] [12] [13] [14] . The recently introduced combination of mutation markers with DNA methylation markers has yielded substantially improved test performance 13, 15, 16 . Methylation markers on their own, either alone or combined, have also yielded promising results, while the assays are technically less demanding [17] [18] [19] [20] [21] [22] [23] . Methylation markers are appealing for CRC screening even more since DNA methylation is an early event in colorectal development, preceding chromosomal abnormalities and mutations 24 .
Yet, the ultimate marker, or combinations of markers, for stool DNA testing still remains to be determined. To this end, in the present study, we aimed to identify new hypermethylated genes in CRC by applying dedicated bioinformatics to microarray expression data of colorectal adenomas and carcinomas and to explore their potential in whole stool DNA testing for CRC 25, 26 . Furthermore, we set out to evaluate complementary value of such markers to FIT in a series of stool sub-samples.
Materials & Methods

Cell line authentication
The CRC cell line HT29 was obtained from the American Type Culture Collection (LGC Standards GmbH, Wesel, Germany). COLO205, Colo320, HCT 116, and RKO cell lines were kindly provided by Dr. G.J. Peters, Department of Oncology, VU University Medical Center, Amsterdam, The Netherlands. The method for authentication was by array comparative genomic hybridization (aCGH, 244k Agilent oligonucleotide platform), performed at the VU University Medical Center, Amsterdam, The Netherlands, most recently in Oktober 2008. The patterns of chromosomal changes observed were in concordance to the previously described chromosomal changes in these cell lines 27 . LS513 was kindly provided by Dr. F. Praz, Centre de Recherche Saint-Antoine, Paris, France. Array CGH confirmed the genomic profile as described in literature (the Wellcome Trust Sanger Institute Cancer Genome Project web site 28 .
Strategy for methylation marker selection
The strategy used for identification and validation of new colon cancer specific methylation markers included both bioinformatics analysis of microarray based mRNA expression data and experimental validations of methylation levels as outlined in supplementary figure 1. First, genes downregulated in CRC compared to adenomas were subjected to a bioinformatics strategy for predicting cancer-specific methylation 25 . In the experimental validation, the presence of DNA methylation was tested by methylation specific PCR (MSP) using the BioTrove OpenArray TM platform 29 (BioTrove, Inc. Woburn, MA, USA), and high-throughput LightCycler assays. Full details are provided in the supplementary methods.
Strategy for evaluating PHACTR3 methylation as a marker in CRC tissue and stool
Cell lines
For validating PHACTR3 methylation in CRC two different regions around the Transcription Start Site (TSS) were investigated for the presence of methylation in six CRC cell lines; regions -149 to -63 bp and +411 to +526 relative to the TSS. Next, HT29 and HCT116 cells were treated with 5-aza-2'-deoxycytidine (5-AZA) to evaluate the effect of demethylation on mRNA expression.
Tissue
PHACTR3 methylation levels in the region +411 to +526 relative to the TSS as well as mRNA expression were measured in cancer and matched normal tissue samples from nine CRC patients by quantitative MSP and quantitative RT-PCR, respectively. Then, PHACTR3 methylation levels were evaluated in an independent series of 34 normal colon mucosa tissue samples from cancer-free patients, 71 advanced adenomas, and 64 carcinomas. Finally, to evaluate the specificity of PHACTR3 hypermethylation for CRC, methylation levels in other tumor types were analyzed, being tumor tissue samples from 44 breast, 20 cervix, 20 lung, 11 esophagus (5 adenocarcinomas and 6 squamous cell carcinomas), 20 gliomas, 19 pancreas and 15 stomach.
Stool
To test the performance of PHACTR3 in a stool-based methylation test for CRC, a collection of 193 whole stool samples was split in a training set and a validation set of equal sizes. The training set consisted of a total of 100 stool samples, of which 66 from patients without colorectal neoplasia (58 healthy controls, 4 patients with colonic diverticula and 4 patients with hemorrhoids), 9 from patients with hyperplastic polyps, 3 from patients with non-advanced adenoma, and 22 from CRC patients. The training set was designed with more controls then cases, to better assess specificity. The validation set consisted of a total of 93 stool samples, 30 of which from healthy individuals, 19 from patients with advanced adenoma and 44 from CRC patients. The validation set contained more advanced neoplasia, including advanced adenomas, to better assess sensitivity. (Patient  characteristics are described in supplementary table 3 ). In addition, methylation data for two other markers, i.e. GATA4 and OSMR were available for comparison in 95% of cases and 91% of controls from the training set and in all stool samples from the validation set tested for PHACTR3 18, 20 . Moreover, to examine the complementary value to FIT, an independent series of 92 stool sub-samples was analyzed for both FIT and PHACTR3 methylation. This stool series originated from a retrospective collection from referral subjects, and included 48 stool samples from subjects without colon neoplasia, 24 from patients with advanced adenomas and 20 from patients with carcinomas.
All details on tissue and stool collection, sample processing, and methodologies used, are presented in the supplementary methods.
Statistical analysis of DNA methylation in tissues and stool
Mean differences in methylation or mRNA expression levels in tissue samples were analyzed with the Mann Whitney test or ANOVA. The relation between methylation levels in stool and the presence or absence of an advanced lesion was studied by Receiver Operator Characteristic (ROC) analysis. The Area Under the Curve (AUC) was used as a measure of the test performance. Confidence intervals of proportions were calculated using the Wilson score method. To test whether age or gender were confounders in the relation between methylation levels and the presence or absence of a lesion, linear regression was used. For the combination of FIT and PHACTR3 methylation, we used a distribution-free rank-based method 30 to calculate linear combination of the two markers giving highest diagnostic accuracy. Sensitivities were compared to FIT or PHACTR3 methylation alone at fixed specificities of 92%, 96%, and 98% using McNemar's test. Calculations for the combination of FIT and PHACTR3 methylation was performed in the R package (version 2.8.1.). All other analyses were performed using SPSS software (version 15.0; SPSS Inc., Chicago, IL, USA). P-values ≤0.05 were considered statistically significant.
Results
Bioinformatics for discovery of candidate genes
A total of 397 genes were downregulated in carcinomas compared to adenomas as determined by mRNA expression microarray analysis (Wilcoxon Rank test p-value <1e-5 and Thas p-value <0.05 (FDR < 0.05)) 26 . In 284 of these genes, a reported transcription start site (TSS) could be identified. These were subsequently subjected to a bioinformatics approach to predict cancer-specific methylation 25 . This yielded 18 candidate genes, of which Phosphatase and actin regulator 3 (PHACTR3, NM_080672) was the only one that passed all further steps of experimental validation (see supplementary figure 1 and supplementary table 1).
PHACTR3 methylation and mRNA expression analysis in CRC cell lines and cancer and matched normal tissues
PHACTR3 harbors a dense CpG island located -678 and +1353 bp relative to the TSS (GC content: 65 %, CpG(obs) / CpG(exp): 1.17). We designed conventional MSP primers in a region -149 to -63 bp and +411 to +526 relative to the TSS (see supplementary methods and supplementary figure 2). The region +411 to +526 relative to the TSS is located in exon 1 and is the same region as analyzed at the initial screen and validation of methylation status (see supplementary figure 1 and supplementary figure 2A) . Of six cell lines tested, only HCT116 showed methylation in the region -149 to -63 bp relative to the TSS. For the region +411 to +526 relative to the TSS, methylation was found in all six cell lines tested (see supplementary figure 2). At the mRNA level these six CRC cell lines only showed marginal PHACTR3 expression levels compared to the positive control (brain tissue) (see supplementary figure 2 ). Treatment of HT29 and HCT116 with the demethylating agent 5-AZA resulted in re-expression of the gene (see supplementary figure 2), consistent with PHACTR3 expression being downregulated by methylation in these cell lines.
Next, PHACTR3 methylation levels as well as mRNA expression were measured in cancer tissue and matched normal tissue from nine CRC patients. All nine CRC tissue samples showed significantly increased methylation levels compared to their normal counterparts. While mRNA expression levels were low in both normal and tumor tissues, still in 6 out of 9 tumors PHACTR3 was significantly downregulated compared to expression levels in their normal counterparts (see figure 1 ).
PHACTR3 methylation analysis in colorectal advanced adenoma and carcinoma tissues
To confirm the differential levels of PHACTR3 methylation in CRC compared to normal mucosa, we tested an independent series of tissue samples and included a set of advanced adenomas as well. PHACTR3 methylation levels were 72-fold and 71-fold higher in advanced adenoma and carcinoma samples, respectively, compared to normal mucosa samples (see figure 2A , p < 0.01). ROC analysis yielded an AUC of 0.93 (CI 95% = 0.87-0.98,) for CRC and 0.95 (CI 95% = 0.93-0.98, see figure 3A ) for advanced neoplasia (advanced adenomas and carcinomas) (see figure 3) . When fixing the cut-off for specificity at 100%, 72% of CRC and 81% of advanced neoplasia could be discriminated from normal mucosa. No significant differences in methylation levels were observed between advanced adenoma and carcinoma tissue samples nor between carcinomas of different UICC stages (p = 0.5 and p=0.07, respectively). Age or gender were no confounding factors (p=0.1 and p=0.9, respectively). Methylation levels in other tumor types showed high levels of methylation in tissue samples from tumors of the intestinal tract (pancreatic, gastric and esophageal cancer) as well as in cervical cancer, while Quantifications represent mean methylation levels and (error bars correspond to standard deviation) relative to methylation levels in the normal tissues from three independent experiments. Methylation levels are calculated as (relative quantity of methylated PHACTR3 / relative quantity of unmethylated Beta-actin (ACTB)) ratio x 1000. Asterisks mark significant differences (p<0.05). B. mRNA expression analysis of PHACTR3 by RT-PCR in tumor (T) and matched normal (N) tissues from nine CRC patients. Quantifications represent mean expression values (error bars correspond to standard deviation) relative to expression levels in the normal tissue from three independent experiments. lower levels of methylation were seen in cancers of lung and bladder, and little or no methylation was seen in cancers of breast, prostate and brain (glioma) (supplementary figure 3).
Sensitivity and specificity of PHACTR3 methylation in stool for detecting colorectal cancer
To investigate the performance of PHACTR3 methylation as a biomarker for CRC detection in stool, we measured methylation levels in two independent series of stool derived DNA samples (see figure 2B and 2C). A training set was used to determine the optimal cut-off to detect CRC patients compared to controls and non-advanced adenoma patients. The validation set was used to validate the results from the training set and to test the detection rate of advanced adenomas.
Training set
The training set consisted of 100 stool samples from individuals who all had undergone complete colonoscopy. ROC analysis of CRC (n=22) compared to non-advanced adenomas and control samples (n=78) yielded an AUC of 0.77 (CI 95% = 0.64-0.90, see figure 3B ). Maximum sensitivity at a fixed specificity of 95% (95% CI = 87-98%) was reached at a cutoff value of 82.5 relative copies. At that cutoff, sensitivity was 55% (95% CI =33-75%) for detecting CRC.
Validation set
The validation set consisted of 93 stool samples from individuals who all had undergone complete colonoscopy. ROC analysis with advanced neoplasia (44 CRC and 19 advanced adenoma) compared to healthy controls (n=30) resulted in an AUC of 0.83 (CI 95% = 0.75-0.91, see figure 3C ). Using a cutoff of value of 82.5 relative copies as defined with the training set yielded a specificity of 100% (CI 95% = 86-100%), a sensitivity of 66% (CI 95% = 50-79%) to detect CRC, and a sensitivity of 32% (CI 95% = 14-57%) to detect advanced adenomas. Using a cutoff of 28 relative copies, the highest possible sensitivity for advanced adenomas was 53% (CI 95% = 32-73%), at a specificity of 93% (CI 95% = 79-98%). Age or gender were no confounding factors (p=1.0 and p=0.4, respectively).
Performance of PHACTR3 in comparison to other stool methylation markers
In order to compare the test performance of PHACTR3 methylation to other stool methylation markers, detection rates were compared to those obtained with the previously published markers, GATA4 18 and OSMR
20
, which were tested by QMSP in a large proportion of the current training and validation series of stool samples. With the stool training set, the cut-offs for GATA4 and OSMR were determined to detect CRC at equal specificities as PHACTR3. Table 1 shows the AUC, the cut-offs, sensitivities and specificities of these three markers. Compared to OSMR, in the training set, PHACTR3 showed a higher AUC and sensitivity (52% versus 29%) for carcinomas, and in the validation set PHACTR3 showed a higher sensitivity for both advanced adenomas (32% versus 21%) and carcinomas (66% versus 43%) with higher specificity (100% versus 90%). PHACTR3 and GATA4 showed equal AUCs and comparable sensitivities (52% versus 57%) for detecting carcinomas in the training set. In the validation set, PHACTR3 showed a higher sensitivity for both advanced adenomas (32% versus 16%) and carcinomas (66% versus 39%) than GATA4, with higher specificity (100% versus 93%).
The combination of these three markers, calling positive when at least one of the three markers would be positive, increased the sensitivity to detect advanced adenoma from 32% to 42% and the sensitivity to detect carcinoma from 52% to 62% (training set) and from 66% to 68% (validation set), however, at cost of specificity (decreased from 94% to 87% and from 100% to 83% for the training and validation set, respectively).
Combination of FIT and PHACTR3 methylation in stool
To investigate whether FIT and PHACTR3 methylation would have complementary value for detecting colorectal cancer and advanced neoplasia, both tests were evaluated in an independent series of stool sub-samples. Because for DNA methylation analysis, the stool sub-samples were processed in a different way compared to whole stool samples, different cut-offs were used, based on ROC analysis, to determine sensitivity and specificity (see supplementary methods). The sensitivities to detect advanced adenomas was 21% (5/24, CI95% 9-40%) for PHACTR3 as well as for FIT. Combining PHACTR3 with FIT, meaning positive for at least one of the two measurements, increased the sensitivity to 33% (7/24, CI 95% 18-53%). The sensitivities to detect CRC were 50% (10/20, CI95% supplementary figure 4), revealed 100% specificity.
To evaluate whether the sensitivity of the combination of FIT and PHACTR3 was significantly higher than the sensitivity of either FIT or PHACTR3 methylation alone, we compared the sensitivities at equal specificity of 92%, 96% and 98% (see supplementary methods). ROC analysis resulted in an AUC of 0.97 (CI 95% 0.=0.93-1.0) for CRC and 0.79 (CI 95% 0.=0.69-0.92) for advanced neoplasia (see figure 4) , with sensitivity/specificity combinations of 61%/92%, 55%/96%, and 48%/98% (see table 2 for advanced adenoma and cancer separately). At these specificities, sensitivities for detecting CRC increased up to 15% using the combination of FIT and PHACTR3 methylation compared to FIT alone, although statistical significance was not reached.
Discussion
Stool-based DNA testing is an appealing approach for non-invasive early detection of CRC. Both DNA mutations and DNA promoter hypermethylation have been investigated as targets of potential screening assays, and especially panels of markers have demonstrated promising performance in initial studies. In the present study we applied a bioinformatics approach for identifying novel hypermethylated genes in CRC. This resulted in the identification of PHACTR3 as a new hypermethylated gene in CRC, which showed to have complementary diagnostic power to FIT in a pilot series.
PHACTR3 was first described in 2003 as a protein associated with the nuclear scaffold in human promyelocytic HL-60 leukemia cells. It was found to bind to actin and to the catalytic subunit of Protein Phosphatase 1 (PP1), thereby inhibiting the function of PP1 31 , which in turn can trigger apoptosis and can inhibit oncogenic signaling due to its interaction with pRb
32
. Induced expression of PHACTR3 in HeLa cervical cancer cells stimulated cell spreading and motility 33 . Finally, in a small study of non small cell lung cancer patients gene mutations were found in 6/20 patients, which was associated with shortened overall survival
34
. Yet, looking at PHACTR3 mRNA expression, abundant expression has been found in adult normal human brain and to a lesser extent in ovary, but not in other organs 31 . Accordingly, in the present study we observed high PHACTR3 mRNA expression in human brain tissue, but much lower expression levels in normal colon tissues and again even lower expression in 6 out of 9 matched tumor tissues. While PHACTR3 showed high methylation levels in these 6 tumor tissue samples, methylation levels were equally high in the 3 tumor tissues from patients in which mRNA expression was not decreased compared to their normal counterparts. In addition, a direct correlation between the level of methylation and level of mRNA expression in all 9 tumor tissues could not be demonstrated (Pearson correlation of -0.3, p=0.5, data not shown). Treatment of HT29 and HCT116 cells with the demethylating agent 5-aza did result in re-expression of PHACTR3, however, consistent with the recent observation that methylation in the region of the first exon, which is the case for PHACTR3, is tightly linked to transcriptional silencing 35 . Yet, the possibility that the observed re-expression of PHACTR3 could be secondary to demethylation of another gene or locus then PHACTR3 itself cannot be excluded. Although a direct relationship between PHACTR3 hypermethylation and silencing of expression in CRC remains to be established, the fact that PHACTR3 methylation is highly associated with cancer still makes it an interesting candidate biomarker.
Levels of PHACTR3 methylation in CRC tissues were prominently high and could significantly discriminate advanced adenoma and carcinoma from normal mucosa at the tissue level. High methylation levels are important for obtaining a good signal to noise ratio in a stool-based assay, especially when lesions to be detected are small. Interestingly, advanced adenoma tissue samples showed methylation levels as high as carcinoma tissues, making PHACTR3 methylation attractive as a biomarker, in compliance with recent guidelines which have stated that the detection of advanced adenomas and not only early carcinoma should be the goal of CRC screening
.
When further exploring its potential as a biomarker, in whole stool samples a sensitivity of 55 -66% for detecting CRC and a sensitivity of 32% for detecting advanced adenoma was observed at a specificity of 95-100%. The test performance of PHACTR3 can be further improved, which is illustrated by the higher AUC in tissues compared to stool, in particular the sensitivity to detect advanced adenomas. With the currently used method higher sensitivities could also be reached, however, at cost of specificity. The highest sensitivity that could be reached to detect advanced adenomas for example was 53%, resulting in a specificity of 93%. With these test performances, PHACTR3 methylation is one of the best performing single methylation markers described so far 14, 14 . Also in comparison to two previously published stool methylation markers GATA4 and OSMR, PHACTR3 showed superior test performance.
A strategy to improve test performance is to combine multiple markers in a single assay. Especially the high specificity makes PHACTR3 attractive as a marker for such a panel that would have increased sensitivity without major effects on specificity. The combination of PHACTR3 with GATA4 and OSMR in the present study indeed did increase sensitivity, but at cost of specificity, which mainly is due to the lower individual specificities of GATA4 and OSMR. Nevertheless it will be difficult to reach 100% sensitivity with methylation markers only, since a portion of CRCs have no or low frequencies of methylated genes, the so-called CpG Island Methylator Phenotype (CIMP)-negative tumors 37 . Therefore, an attractive alternative could be to combine methylation markers with a completely different marker like FIT. Since FIT is already being used in several screening programs throughout the world and logistics have already been put in place, adding a DNA methylation marker would be relatively easy. We therefore performed a pilot study on the performance of PHACTR3 methylation in combination with FIT. The combination of FIT and PHACTR3 methylation increased the sensitivity for advanced neoplasia, i.e. adenomas and CRC taken together, while maintaining a high specificity. These experiments were done in a series of stool sub-samples, which would be a good alternative for whole stool samples concerning logistics, stool processing, and storage of samples in large-scale screening programs. Because these stool sub-samples were processed in a different manner compared to the whole stool samples described above, systematic differences exist when comparing these results to those from whole stool samples 4 . Still, the results obtained demonstrate the power of combining FIT with a DNA methylation marker. This is in line with recent findings that showed an improved test performance of combining other molecular markers (i.e. APC, BAT26 and long-DNA) with FOBT 12, 38 .
In conclusion, using a bioinformatics approach, PHACTR3 was identified as a new hypermethylated gene in CRC. Although we could not unravel the functional effect of PHACTR3 hypermethylation in CRC, we clearly showed its high potential as a biomarker in stool-based DNA testing. Furthermore, the present study suggests that combining PHACTR3 methylation with FIT could be particularly promising. The full potential of this marker or its combination with FIT awaits validation in a larger, well-controlled cohort study to test its performance in an asymptomatic population.
Supplementary methods
OpenArrayTM and Lightcycler® experiments
A first screen for the presence of methylation was done by methylation specific PCR (MSP) on a BioTrove OpenArrayTM platform 1 (BioTrove, Inc. Woburn, MA, USA) on 83 normal mucosa and 80 carcinoma tissues. Whenever possible, we designed primers covering different transcript variants. MSP reactions were performed in 33 nL reactions based on SYBR® Green I chemistry. A sample was considered to be methylated if the Ct value was less than 42 and Tm fell within an automatically derived marker-specific Tm interval (personal communication Wim van Criekinge). To validate the presence of methylation, we selected genes that were methylated in >25% of CRC samples and in <15% of normal mucosa samples (see supplementary table 1 ). Two genes, Fucokinase (FUK, NM_145059) and Phosphatase and actin regulator 3 (PHACTR3, NM_080672), met these criteria and presence of methylation was validated by means of high through-put LightCycler MSP in a subset of the series used for OpenArrayTM experiments, consisting of 48 normal mucosa and 42 CRC tissues samples. MSP reactions on the LightCycler® were based on SYBR® Green I chemistry using a total reaction volume of 10 µl. Further analysis of FUK was hampered by technical issues. For PHACTR3 we were able to create robust MSP assays to study the methylation status in more detail.
Tissue samples and DNA isolation
Tissues from 34 normal colon mucosa from cancer-free patients, 71 advanced colon adenomas and 64 colon carcinomas were collected from the tissue archive of the department of pathology at the VU University medical center, Amsterdam, The Netherlands (for patient characteristics, see supplementary table 2). Adenomas were defined as advanced when ≥10 mm, harboring any villous features (i.e. tubulovillous or villous adenoma) and/or high-grade dysplasia. DNA from formalin-fixed paraffinembedded (FFPE) was extracted by a column-based method (QIAamp DNA micro kit, Qiagen, Hilden, Germany) as described before 2, 3 . DNA from snap-frozen tissues was isolated using TRIzol (Invitrogen, Breda, NL) following the supplier's instructions. DNA was quantified using the Nanodrop 1000 UV spectrophotometer (Nanodrop Technologies Inc, Wilmington, DE, USA).
In addition, independent series of FFPE tissues were collected from the tissue archive from the University Hospital Liège, Belgium and from the Maastricht University Medical Center, The Netherlands. All samples were used in compliance with the institutional regulations for use of patient material. DNA was isolated from 9 CRC tissues and matched distant normal colon tissues, from 163 independent colon tissues [83 normal colon mucosas (41 from cancer-free patients and 42 from resection margins from CRC patients) and 80 CRCs], and from cancer tissues of other origin [44 breast, 20 cervix, 20 lung, 11 esophagus (5 adenocarcinomas and 6 squamous cell carcinomas), 20 gliomas, 19 pancreas and 15 stomach]. Per sample 15 sections of 10µm were deparaffinized and DNA extraction was performed using phenol/chloroform extraction and resuspended in 80 µl of LoTE (3 mmol/L Tris, 0.2 mmol/L EDTA, pH 8.0). DNA was quantified using the PicoGreen dsDNA quantitation kit (Molecular Probes, Invitrogen, CA, USA).
Stool samples and DNA isolation
Whole stool samples
Whole stool samples from subjects with either no colon neoplasia, hyperplastic polyps, or (advanced) adenomas were collected from subjects over 50 years of age who underwent primary colonoscopy screening for CRC within the framework of a workplace-based community colorectal cancer study at the Maastricht University Medical Center and from referral subjects who underwent colonoscopy at the VU University Medical Center in Amsterdam. Stool samples from colonoscopy-confirmed CRC patients who were diagnosed with all stages of CRC were collected at the VU University Medical Center in Amsterdam and from a multicenter prospective trial in Germany, in compliance with the institutional ethical regulations. All stool samples were collected prior to colonoscopy and before the start of laxative treatment preceding colonoscopy. All colonoscopies were performed or supervised by experienced endoscopists. Stool stabilization buffer was added to the stool sample by the subject immediately after defecation (Exact Sciences, Madison, WI, USA), processed in the lab within 48 hours, and stored at -80 o C until use. Written informed consent was obtained from all subjects who provided stool samples. Stool samples were split into two independent sets of noncancerous control subjects and colorectal cancer patients. The training set consisted of 66 stool samples from patients without colon neoplasia (58 healthy controls, 4 with colonic diverticula and 4 with hemorrhoids), 9 stool samples from patients with hyperplastic polyps, 3 stool samples from patients with non-advanced adenoma, and 22 stool samples from CRC patients. The validation set consisted of 30 control stool samples from healthy individuals, 19 stool samples from patients with advanced adenoma and 44 stool samples from CRC patients (patient characteristics are described in Supplementary table 3). For recovery of human DNA, whole stool samples were homogenized in a sevenfold excess volume of stool stabilization buffer and aliquoted in 32-mL portions that contained the equivalent of 4 g of stool each. DNA isolation was performed as described before (4) . Tumor tissue DNA of these patients was not available.
Stool sub-samples
Stool sub-samples were obtained from a retrospective collection from referral subjects who underwent colonoscopy at the VU University Medical Center in Amsterdam, The Netherlands. Stool samples were collected between November 2004 and January 2007 from referred subjects 1 day before colonoscopy, immediately stored at 4 o C and transferred to -20 o C at the day of the colonoscopy without stabilization buffer. Stool samples from subject subjects with no colon neoplasia (n=48), advanced adenoma (n=24) or carcinoma (n=20) were used in this study. Written informed consent was obtained from all subjects who provided stool samples. This study was approved by the Medical Ethical Committee of the VU University Medical Center. Patient characteristics are described in Supplementary table 4. At the start of the experiments, stool samples were thawed and after performing FIT, ~1 g stool was sampled from each stool sample and homogenized in a twofold excess volume of stool stabilization buffer (Exact Sciences) for DNA extraction. DNA was isolated using the QIAamp DNA Stool mini kit (Qiagen, Hilden, Germany). Homogenized stool (250 µl) was used as starting material for each DNA extraction. DNA was eluted in a volume of 75 µl and DNA from three separate isolations from the same sample was pooled.
Sodium Bisulfite conversion and Quantitative Methylation Specific PCR (QMSP)
For cell line and tissue DNA, 500 ng was sodium bisulfite-converted using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions and eluted in 50 μl Tris/HCL pH8.0. For DNA from whole stool samples, 2 μg was subjected to bisulfite modification in 96-wells format on a pipetting robot (Tecan), using the EZ-96DNA Methylation kit (Zymo Research), according to the manufacturer's protocol and eluted in 30 μl Tris/HCL pH8.0. For DNA from partial stool samples, 2 μg of DNA or, when the required volume exceeded the maximum volume according to the protocol, a total of 45 μl was subjected to bisulfite modification using the EZ DNA methylation kit (Zymo Research) according to the manufacturer's protocol and eluted in 25 μl Tris/HCL pH8.0.
Conventional MSP was performed on CRC cell lines as described before 4 with 2 μl bisulfitemodified DNA in a 25 μl volume using 0.5 U of JumpStart Red Taq DNA polymerase (Sigma Aldrich, Zwijndrecht, The Netherlands). MSP products were analyzed on a 3% agarose gel containing ethidium bromide.
Quantitative MSP (QMSP) on tissue and stool samples was performed on a 7500 fast PCR system and 7900HT real-time PCR system (Applied Biosystems Foster City, CA) as described before 5 , with 5 µl of bisulfite-modified DNA per reaction. Tissue samples were analyzed in duplicate. Due to their limited amount, stool samples were analyzed in one real-time experiment. Methylation levels in tissues were calculated as 1000 x (relative quantity of methylated PHACTR3/relative quantity of Beta-actin (ACTB)). In stool samples, the relative quantities of PHACTR3 were used as methylation level (no ratio was calculated). Only Ct values <40 were included in the calculation. Primer sequences are listed in Supplementary table 5.
Reverse transcriptase PCR (RT-PCR)
Total RNA from cell lines was isolated using TRIzol reagent (Invitrogen, Breda, NL), and subjected to purification using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). After DNase treatment (RQ1 DNAse, Promega, Leiden, The Netherlands), cDNA was made with the Iscript cDNA Synthesis Kit (BioRad, Veenendaal, The Netherlands). Quantitative RT-PCR was done using SYBR Green PCR master mix (Applied Biosystems, Nieuwerkerk a/d IJssel, NL) as described before 6 , with 0.25 μM of each primer and 50 ng cDNA. Relative expression levels were determined by calculating the Ct-ratio, using B2M as a reference (Ct ratio = 2^-(Ct PHACTR3 -Ct B2M)). Primer sequences are provided in Supplementary Table 5 .
Fecal Immunochemical Test analysis
FIT's (OC-sensor®, Eiken Chemical Co., Tokyo, Japan) were processed with the OC sensor MICRO desktop analyzer (Eiken Chemical) and analyzed according to the manufacturer's instructions.
Supplementary figure 3. PHACTR3 DNA methylation levels in different tumor types. PHACTR3 methylation levels in carcinomas from brain (glioma, n=20), prostate (n=19), breast (n=37), bladder (n=14), lung (n=16), cervix (n=18), pancreas (n=18), gastric (n=14) and esophagus (n=7) are shown as (relative quantity of methylated PHACTR3/ relative quantity of unmethylated Beta-actin (ACTB)) ratio x 1000. Box plots show first quartile, median, third quartile and range of methylation levels. Dots represent individual data points, asterisks represent extremes. The percentages show a range of methylation found in different regions of the same gene based on testing a total of 80 carcinoma tissues and 83 normal colon tissues; NA, not available
